Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Equity

Seres Therapeutics (MCRB) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Seres Therapeutics (MCRB) over the last 9 years, with Q3 2025 value amounting to 6403.7%.

  • Seres Therapeutics' EBIT Margin changed N/A to 6403.7% in Q3 2025 from the same period last year, while for Sep 2025 it was 29466.95%, marking a year-over-year increase of 1728814900.0%. This contributed to the annual value of 154.44% for FY2023, which is 23696100.0% up from last year.
  • According to the latest figures from Q3 2025, Seres Therapeutics' EBIT Margin is 6403.7%.
  • Over the past 5 years, Seres Therapeutics' EBIT Margin peaked at 53.98% during Q3 2021, and registered a low of 57850.0% during Q4 2023.
  • For the 4-year period, Seres Therapeutics' EBIT Margin averaged around 8085.74%, with its median value being 1716.23% (2022).
  • The largest annual percentage gain for Seres Therapeutics' EBIT Margin in the last 5 years was 52468100bps (2023), contrasted with its biggest fall of -576724600bps (2023).
  • Over the past 4 years, Seres Therapeutics' EBIT Margin (Quarter) stood at 684.56% in 2021, then soared by 74bps to 177.54% in 2022, then plummeted by -32484bps to 57850.0% in 2023, then surged by 89bps to 6403.7% in 2025.
  • Its last three reported values are 6403.7% in Q3 2025, 57850.0% for Q4 2023, and 14382.58% during Q3 2023.